538 related articles for article (PubMed ID: 23400079)
1. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
Papavasileiou E; Steel DH; Liazos E; McHugh D; Jackson TL
Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
3. Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent.
de Silva SR; Bindra MS
Eye (Lond); 2016 Jul; 30(7):952-7. PubMed ID: 27080482
[TBL] [Abstract][Full Text] [Related]
4. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Cho HJ; Koh KM; Kim JH; Kim HS; Han JI; Lew YJ; Lee TG; Kim JW
Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration.
Iacono P; Parodi MB; Introini U; La Spina C; Varano M; Bandello F
Retina; 2014 Feb; 34(2):281-7. PubMed ID: 23851632
[TBL] [Abstract][Full Text] [Related]
8. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator.
Kimura S; Morizane Y; Hosokawa M; Shiode Y; Kawata T; Doi S; Matoba R; Hosogi M; Fujiwara A; Inoue Y; Shiraga F
Am J Ophthalmol; 2015 Apr; 159(4):683-9. PubMed ID: 25555798
[TBL] [Abstract][Full Text] [Related]
9. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
Fassbender JM; Sherman MP; Barr CC; Schaal S
Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage.
Mayer WJ; Hakim I; Haritoglou C; Gandorfer A; Ulbig M; Kampik A; Wolf A
Acta Ophthalmol; 2013 May; 91(3):274-8. PubMed ID: 21952010
[TBL] [Abstract][Full Text] [Related]
11. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ
Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
14. Vitreous hemorrhage complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage.
Wu TT; Kung YH; Hong MC
Retina; 2011 Nov; 31(10):2071-7. PubMed ID: 21817964
[TBL] [Abstract][Full Text] [Related]
15. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ
Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
[TBL] [Abstract][Full Text] [Related]
17. Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
Bardak H; Bardak Y; Erçalık Y; Erdem B; Arslan G; Timlioglu S
Eur J Ophthalmol; 2018 May; 28(3):306-310. PubMed ID: 29148027
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal recombinant tissue plasminogen activator without and with additional gas injection in patients with submacular haemorrhage associated with age-related macular degeneration.
Tsymanava A; Uhlig CE
Acta Ophthalmol; 2012 Nov; 90(7):633-8. PubMed ID: 21332673
[TBL] [Abstract][Full Text] [Related]
19. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement.
Hassan AS; Johnson MW; Schneiderman TE; Regillo CD; Tornambe PE; Poliner LS; Blodi BA; Elner SG
Ophthalmology; 1999 Oct; 106(10):1900-6; discussion 1906-7. PubMed ID: 10519583
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage.
Kung YH; Wu TT; Hong MC; Sheu SJ
J Ocul Pharmacol Ther; 2010 Oct; 26(5):469-74. PubMed ID: 20925578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
